Table 4

GEE results (OR (95% CI)) for the outcomes erosion progression, joint space narrowing progression and Sharp–van der Heijde progression yes/no, showing the association between swelling, tenderness and joint damage progression split for baseline and follow-up clinical assessments

Erosion progressionJSN progressionSHS progression
Swollen neverReferenceReferenceReference
 Only swollen at baseline1.2 (0.77 to 1.9)1.6 (1.1 to 2.4)1.3 (0.98 to 1.8)
 Only swollen during follow-up, 1×2.0 (1.1 to 3.4)1.5 (0.91 to 2.7)1.8 (1.2 to 2.8)
 Only swollen during follow-up, ≥2×2.7 (1.5 to 4.6)2.4 (1.1 to 5.4)2.0 (1.2 to 3.3)
 Swollen at baseline and during follow-up3.2 (2.1 to 4.9)3.3 (2.2 to 4.9)3.0 (2.2 to 4.0)
Tender neverReferenceReferenceReference
 Only tender at baseline1.2 (0.77 to 2.0)1.3 (0.83 to 2.1)1.4 (0.99 to 2.0)
 Only tender during follow-up, 1×2.0 (1.1 to 3.4)1.4 (0.86 to 2.3)1.7 (1.1 to 2.5)
 Only tender during follow-up, ≥2×3.8 (2.3 to 6.3)3.3 (1.9 to 5.7)3.4 (2.2 to 5.2)
 Tender at baseline and during follow-up3.6 (2.5 to 5.4)3.2 (2.1 to 4.8)3.3 (2.4 to 4.5)
  • All corrected for: total SHS baseline, erosions at baseline yes/no per joint (for outcome erosion progression) JSN at baseline yes/no per joint (for outcome JSN progression), SHS at baseline yes/no per joint (for outcome SHS progression), age, gender, body mass index, rheumatoid factor (RF)/anti-CCP2 status (double positive, RF-positive or CCP2-positive, double negative), treatment group and erythrocyte sedimentation rate.

  • CCP, cyclic citrullinated peptide; GEE, generalised estimating equations; JSN, joint space narrowing; SHS, Sharp–van der Heijde score.